Yonemura Y, Nakai Y, Takamura H, Kaji M, Ninomiya I, Tsugawa K, Sugiyama K, Fujimura T, Miyazaki I, Endou Y, Tanaka M, Sasaki T, Hashimoto T
KANAZAWA UNIV,CANC RES INST,DEPT EXPTL THERAPEUT & BIOPHYS,KANAZAWA,ISHIKAWA 920,JAPAN. KANAZAWA UNIV,DEPT LAB MED,KANAZAWA,ISHIKAWA 920,JAPAN.
Int J Oncol. 1993 Aug;3(2):325-9.
A new tumor marker was tested (serum erbB-2 protein) in 128 patients with gastric cancer and 110 patients with benign gastric diseases, and the results were correlated with erbB-2 tissue status and clinicopathological parameters. Abnormal level of erbB-2 protein was found in 15/128 (12%) of gastric cancer patients and in 2/110 (2%) of benign gastric diseases. Elevated erbB-2 levels did not correlate with age, sex, tumor size, macroscopic type, histologic type, serosal invasion, nodal status, or clinical stage. In all the 15 patients except one case, with abnormally high level of serum erbB-2, erbB-2 immunoreactivity was confirmed in the primary tumors by immunohistochemical staining. The percentage of positive serum levels of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA) and CA 19-9 were 6%, 16% and 20%, respectively. However, there was no relation between serum erbB-2 level and CA 19-9, CEA or AFP level. If the CA 19-9 was assayed in combination with erbB-2, the overall sensitivity was 30%. In addition, the combination of the three markers of erbB-2, CEA and CA 19-9 gave a sensitivity of 41%. Patients with abnormal erbB-2 serum level run poorer prognoses than did the patients with normal erbB-2 serum level. We conclude that erbB-2 protein is an attractive tumor marker, and a powerful prognostic indicator of gastric cancer patients.
在128例胃癌患者和110例良性胃部疾病患者中检测了一种新的肿瘤标志物（血清erbB-2蛋白），并将结果与erbB-2组织状态及临床病理参数进行关联分析。128例胃癌患者中有15例（12%）血清erbB-2蛋白水平异常，110例良性胃部疾病患者中有2例（2%）异常。erbB-2水平升高与年龄、性别、肿瘤大小、大体类型、组织学类型、浆膜侵犯、淋巴结状态或临床分期均无关联。除1例血清erbB-2水平异常高的患者外，其余15例患者的原发性肿瘤经免疫组化染色均证实有erbB-2免疫反应性。甲胎蛋白（AFP）、癌胚抗原（CEA）和CA 19-9血清阳性率分别为6%、16%和20%。然而，血清erbB-2水平与CA 19-9、CEA或AFP水平之间无关联。若将CA 19-9与erbB-2联合检测，总体敏感性为30%。此外，erbB-2、CEA和CA 19-9这三种标志物联合检测的敏感性为41%。血清erbB-2水平异常的患者预后比血清erbB-2水平正常的患者差。我们得出结论，erbB-2蛋白是一种有吸引力的肿瘤标志物，也是胃癌患者强有力的预后指标。
